APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mycosis Fungoides Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Mycosis Fungoides Therapeutics Market Analysis and Forecast 2026-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchMycosis Fungoides Therapeutics Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Mycosis Fungoides Therapeutics Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Mycosis Fungoides Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mycosis Fungoides Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Mycosis Fungoides Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Mycosis Fungoides Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Mycosis Fungoides Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Mycosis Fungoides Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Mycosis Fungoides Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Mycosis Fungoides Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Mycosis Fungoides Therapeutics include Kyowa Kirin Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck & Co. Inc., Soligenix Inc., Seattle Genetics Inc., Horizon Therapeutics Plc, Helsinn Healthcare SA and Celgene Corp., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Mycosis Fungoides Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Mycosis Fungoides Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Mycosis Fungoides Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Mycosis Fungoides Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Mycosis Fungoides Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Mycosis Fungoides Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Mycosis Fungoides Therapeutics Segment by Company

Kyowa Kirin Co. Ltd.

Takeda Pharmaceutical Co. Ltd.

Eisai Co. Ltd.

Merck & Co. Inc.

Soligenix Inc.

Seattle Genetics Inc.

Horizon Therapeutics Plc

Helsinn Healthcare SA

Celgene Corp.

Azurity Pharmaceuticals Inc.

Mycosis Fungoides Therapeutics Segment by Type

Small Molecules

Biologics

Mycosis Fungoides Therapeutics Segment by Application

Hospital

Clinic

Other

Mycosis Fungoides Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mycosis Fungoides Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mycosis Fungoides Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mycosis Fungoides Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Mycosis Fungoides Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Mycosis Fungoides Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Mycosis Fungoides Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Mycosis Fungoides Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Small Molecules Major Player Table 3. Biologics Major Player Table 4. Global Mycosis Fungoides Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Other Major Player Table 8. Mycosis Fungoides Therapeutics Industry Trends Table 9. Mycosis Fungoides Therapeutics Industry Drivers Table 10. Mycosis Fungoides Therapeutics Industry Opportunities and Challenges Table 11. Mycosis Fungoides Therapeutics Industry Restraints Table 12. Global Mycosis Fungoides Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Mycosis Fungoides Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Mycosis Fungoides Therapeutics Market Share by Region (2021-2026) Table 15. Global Mycosis Fungoides Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Mycosis Fungoides Therapeutics Market Share by Region (2027-2032) Table 17. Global Mycosis Fungoides Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Mycosis Fungoides Therapeutics Revenue Market Share by Players (2021-2026) Table 19. Global Mycosis Fungoides Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Mycosis Fungoides Therapeutics Key Players Headquarters & Area Served Table 21. Global Mycosis Fungoides Therapeutics Players, Product Type & Application Table 22. Global Mycosis Fungoides Therapeutics Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Mycosis Fungoides Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Mycosis Fungoides Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Mycosis Fungoides Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Mycosis Fungoides Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Mycosis Fungoides Therapeutics Revenue Market Share by Type (2021-2026) Table 29. Global Mycosis Fungoides Therapeutics Revenue Market Share by Type (2027-2032) Table 30. Global Mycosis Fungoides Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Mycosis Fungoides Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Mycosis Fungoides Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Mycosis Fungoides Therapeutics Revenue Market Share by Application (2021-2026) Table 34. Global Mycosis Fungoides Therapeutics Revenue Market Share by Application (2027-2032) Table 35. Kyowa Kirin Co. Ltd. Company Information Table 36. Kyowa Kirin Co. Ltd. Business Overview Table 37. Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio Table 39. Kyowa Kirin Co. Ltd. Recent Development Table 40. Takeda Pharmaceutical Co. Ltd. Company Information Table 41. Takeda Pharmaceutical Co. Ltd. Business Overview Table 42. Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio Table 44. Takeda Pharmaceutical Co. Ltd. Recent Development Table 45. Eisai Co. Ltd. Company Information Table 46. Eisai Co. Ltd. Business Overview Table 47. Eisai Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Eisai Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio Table 49. Eisai Co. Ltd. Recent Development Table 50. Merck & Co. Inc. Company Information Table 51. Merck & Co. Inc. Business Overview Table 52. Merck & Co. Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Merck & Co. Inc. Mycosis Fungoides Therapeutics Product Portfolio Table 54. Merck & Co. Inc. Recent Development Table 55. Soligenix Inc. Company Information Table 56. Soligenix Inc. Business Overview Table 57. Soligenix Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Soligenix Inc. Mycosis Fungoides Therapeutics Product Portfolio Table 59. Soligenix Inc. Recent Development Table 60. Seattle Genetics Inc. Company Information Table 61. Seattle Genetics Inc. Business Overview Table 62. Seattle Genetics Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Seattle Genetics Inc. Mycosis Fungoides Therapeutics Product Portfolio Table 64. Seattle Genetics Inc. Recent Development Table 65. Horizon Therapeutics Plc Company Information Table 66. Horizon Therapeutics Plc Business Overview Table 67. Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Product Portfolio Table 69. Horizon Therapeutics Plc Recent Development Table 70. Helsinn Healthcare SA Company Information Table 71. Helsinn Healthcare SA Business Overview Table 72. Helsinn Healthcare SA Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Helsinn Healthcare SA Mycosis Fungoides Therapeutics Product Portfolio Table 74. Helsinn Healthcare SA Recent Development Table 75. Celgene Corp. Company Information Table 76. Celgene Corp. Business Overview Table 77. Celgene Corp. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Celgene Corp. Mycosis Fungoides Therapeutics Product Portfolio Table 79. Celgene Corp. Recent Development Table 80. Azurity Pharmaceuticals Inc. Company Information Table 81. Azurity Pharmaceuticals Inc. Business Overview Table 82. Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Product Portfolio Table 84. Azurity Pharmaceuticals Inc. Recent Development Table 85. North America Mycosis Fungoides Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 86. North America Mycosis Fungoides Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 87. North America Mycosis Fungoides Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 88. North America Mycosis Fungoides Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 89. North America Mycosis Fungoides Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America Mycosis Fungoides Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Mycosis Fungoides Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 92. Europe Mycosis Fungoides Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 93. Europe Mycosis Fungoides Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 94. Europe Mycosis Fungoides Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 95. Europe Mycosis Fungoides Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 96. Europe Mycosis Fungoides Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe Mycosis Fungoides Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 98. Europe Mycosis Fungoides Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 99. China Mycosis Fungoides Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 100. China Mycosis Fungoides Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 101. China Mycosis Fungoides Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 102. China Mycosis Fungoides Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia Mycosis Fungoides Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 104. Asia Mycosis Fungoides Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 105. Asia Mycosis Fungoides Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 106. Asia Mycosis Fungoides Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia Mycosis Fungoides Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia Mycosis Fungoides Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 109. Asia Mycosis Fungoides Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 110. SAMEA Mycosis Fungoides Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 111. SAMEA Mycosis Fungoides Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 112. SAMEA Mycosis Fungoides Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 113. SAMEA Mycosis Fungoides Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 114. SAMEA Mycosis Fungoides Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. SAMEA Mycosis Fungoides Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 116. SAMEA Mycosis Fungoides Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Mycosis Fungoides Therapeutics Image Figure 2. Global Mycosis Fungoides Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mycosis Fungoides Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Small Molecules Image Figure 5. Biologics Image Figure 6. Global Mycosis Fungoides Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Mycosis Fungoides Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Other Image Figure 11. Global Mycosis Fungoides Therapeutics Market Size (US$ Million) & (2021-2032) Figure 12. Global Mycosis Fungoides Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Mycosis Fungoides Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Mycosis Fungoides Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Mycosis Fungoides Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Mycosis Fungoides Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Mycosis Fungoides Therapeutics Revenue Market Share by Type (2021-2032) Figure 19. Global Mycosis Fungoides Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Mycosis Fungoides Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Mycosis Fungoides Therapeutics Revenue Market Share by Application (2021-2032) Figure 22. North America Mycosis Fungoides Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Mycosis Fungoides Therapeutics Revenue Share by Type (2021-2032) Figure 24. North America Mycosis Fungoides Therapeutics Revenue Share by Application (2021-2032) Figure 25. North America Mycosis Fungoides Therapeutics Revenue Share by Country (2021-2032) Figure 26. United States Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Mycosis Fungoides Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Mycosis Fungoides Therapeutics Revenue Share by Type (2021-2032) Figure 31. Europe Mycosis Fungoides Therapeutics Revenue Share by Application (2021-2032) Figure 32. Europe Mycosis Fungoides Therapeutics Revenue Share by Country (2021-2032) Figure 33. Germany Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Mycosis Fungoides Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Mycosis Fungoides Therapeutics Revenue Share by Type (2021-2032) Figure 43. China Mycosis Fungoides Therapeutics Revenue Share by Application (2021-2032) Figure 44. Asia Mycosis Fungoides Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Mycosis Fungoides Therapeutics Revenue Share by Type (2021-2032) Figure 46. Asia Mycosis Fungoides Therapeutics Revenue Share by Application (2021-2032) Figure 47. Asia Mycosis Fungoides Therapeutics Revenue Share by Region (2021-2032) Figure 48. Japan Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Mycosis Fungoides Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Mycosis Fungoides Therapeutics Revenue Share by Type (2021-2032) Figure 56. SAMEA Mycosis Fungoides Therapeutics Revenue Share by Application (2021-2032) Figure 57. SAMEA Mycosis Fungoides Therapeutics Revenue Share by Country (2021-2032) Figure 58. Brazil Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Mycosis Fungoides Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecules
  • Biologics
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Kyowa Kirin Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Eisai Co. Ltd.
  • Merck & Co. Inc.
  • Soligenix Inc.
  • Seattle Genetics Inc.
  • Horizon Therapeutics Plc
  • Helsinn Healthcare SA
  • Celgene Corp.
  • Azurity Pharmaceuticals Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Mycosis Fungoides Therapeutics Market by Type
  3. 1.2.1 Global Mycosis Fungoides Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Small Molecules
  5. 1.2.3 Biologics
  6. 1.3 Mycosis Fungoides Therapeutics Market by Application
  7. 1.3.1 Global Mycosis Fungoides Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Mycosis Fungoides Therapeutics Market Dynamics
  1. 2.1 Mycosis Fungoides Therapeutics Industry Trends
  2. 2.2 Mycosis Fungoides Therapeutics Industry Drivers
  3. 2.3 Mycosis Fungoides Therapeutics Industry Opportunities and Challenges
  4. 2.4 Mycosis Fungoides Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Mycosis Fungoides Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Mycosis Fungoides Therapeutics Growth Trends by Region
  3. 3.2.1 Global Mycosis Fungoides Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Mycosis Fungoides Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Mycosis Fungoides Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Mycosis Fungoides Therapeutics Revenue by Players
  2. 4.1.1 Global Mycosis Fungoides Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Mycosis Fungoides Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Mycosis Fungoides Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Mycosis Fungoides Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Mycosis Fungoides Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Mycosis Fungoides Therapeutics Players, Product Type & Application
  8. 4.5 Global Mycosis Fungoides Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Mycosis Fungoides Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Mycosis Fungoides Therapeutics Tier 1, Tier 2, and Tier 3
5 Mycosis Fungoides Therapeutics Market Size by Type
  1. 5.1 Global Mycosis Fungoides Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Mycosis Fungoides Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Mycosis Fungoides Therapeutics Revenue Market Share by Type (2021-2032)
6 Mycosis Fungoides Therapeutics Market Size by Application
  1. 6.1 Global Mycosis Fungoides Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Mycosis Fungoides Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Mycosis Fungoides Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Kyowa Kirin Co. Ltd.
  2. 7.1.1 Kyowa Kirin Co. Ltd. Company Information
  3. 7.1.2 Kyowa Kirin Co. Ltd. Business Overview
  4. 7.1.3 Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
  6. 7.1.5 Kyowa Kirin Co. Ltd. Recent Developments
  7. 7.2 Takeda Pharmaceutical Co. Ltd.
  8. 7.2.1 Takeda Pharmaceutical Co. Ltd. Company Information
  9. 7.2.2 Takeda Pharmaceutical Co. Ltd. Business Overview
  10. 7.2.3 Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
  12. 7.2.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
  13. 7.3 Eisai Co. Ltd.
  14. 7.3.1 Eisai Co. Ltd. Company Information
  15. 7.3.2 Eisai Co. Ltd. Business Overview
  16. 7.3.3 Eisai Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eisai Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
  18. 7.3.5 Eisai Co. Ltd. Recent Developments
  19. 7.4 Merck & Co. Inc.
  20. 7.4.1 Merck & Co. Inc. Company Information
  21. 7.4.2 Merck & Co. Inc. Business Overview
  22. 7.4.3 Merck & Co. Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck & Co. Inc. Mycosis Fungoides Therapeutics Product Portfolio
  24. 7.4.5 Merck & Co. Inc. Recent Developments
  25. 7.5 Soligenix Inc.
  26. 7.5.1 Soligenix Inc. Company Information
  27. 7.5.2 Soligenix Inc. Business Overview
  28. 7.5.3 Soligenix Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Soligenix Inc. Mycosis Fungoides Therapeutics Product Portfolio
  30. 7.5.5 Soligenix Inc. Recent Developments
  31. 7.6 Seattle Genetics Inc.
  32. 7.6.1 Seattle Genetics Inc. Company Information
  33. 7.6.2 Seattle Genetics Inc. Business Overview
  34. 7.6.3 Seattle Genetics Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Seattle Genetics Inc. Mycosis Fungoides Therapeutics Product Portfolio
  36. 7.6.5 Seattle Genetics Inc. Recent Developments
  37. 7.7 Horizon Therapeutics Plc
  38. 7.7.1 Horizon Therapeutics Plc Company Information
  39. 7.7.2 Horizon Therapeutics Plc Business Overview
  40. 7.7.3 Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Product Portfolio
  42. 7.7.5 Horizon Therapeutics Plc Recent Developments
  43. 7.8 Helsinn Healthcare SA
  44. 7.8.1 Helsinn Healthcare SA Company Information
  45. 7.8.2 Helsinn Healthcare SA Business Overview
  46. 7.8.3 Helsinn Healthcare SA Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Helsinn Healthcare SA Mycosis Fungoides Therapeutics Product Portfolio
  48. 7.8.5 Helsinn Healthcare SA Recent Developments
  49. 7.9 Celgene Corp.
  50. 7.9.1 Celgene Corp. Company Information
  51. 7.9.2 Celgene Corp. Business Overview
  52. 7.9.3 Celgene Corp. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Celgene Corp. Mycosis Fungoides Therapeutics Product Portfolio
  54. 7.9.5 Celgene Corp. Recent Developments
  55. 7.10 Azurity Pharmaceuticals Inc.
  56. 7.10.1 Azurity Pharmaceuticals Inc. Company Information
  57. 7.10.2 Azurity Pharmaceuticals Inc. Business Overview
  58. 7.10.3 Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Product Portfolio
  60. 7.10.5 Azurity Pharmaceuticals Inc. Recent Developments
8 North America
  1. 8.1 North America Mycosis Fungoides Therapeutics Revenue (2021-2032)
  2. 8.2 North America Mycosis Fungoides Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Mycosis Fungoides Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Mycosis Fungoides Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Mycosis Fungoides Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Mycosis Fungoides Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Mycosis Fungoides Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Mycosis Fungoides Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Mycosis Fungoides Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Mycosis Fungoides Therapeutics Revenue by Country
  11. 8.6.1 North America Mycosis Fungoides Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Mycosis Fungoides Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Mycosis Fungoides Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Mycosis Fungoides Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Mycosis Fungoides Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Mycosis Fungoides Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Mycosis Fungoides Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Mycosis Fungoides Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Mycosis Fungoides Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Mycosis Fungoides Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Mycosis Fungoides Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Mycosis Fungoides Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Mycosis Fungoides Therapeutics Revenue by Country
  11. 9.6.1 Europe Mycosis Fungoides Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Mycosis Fungoides Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Mycosis Fungoides Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Mycosis Fungoides Therapeutics Revenue (2021-2032)
  2. 10.2 China Mycosis Fungoides Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Mycosis Fungoides Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Mycosis Fungoides Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Mycosis Fungoides Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Mycosis Fungoides Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Mycosis Fungoides Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Mycosis Fungoides Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Mycosis Fungoides Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Mycosis Fungoides Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Mycosis Fungoides Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Mycosis Fungoides Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Mycosis Fungoides Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Mycosis Fungoides Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Mycosis Fungoides Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Mycosis Fungoides Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Mycosis Fungoides Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Mycosis Fungoides Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Mycosis Fungoides Therapeutics Revenue by Country
  11. 11.6.1 Asia Mycosis Fungoides Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Mycosis Fungoides Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Mycosis Fungoides Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Mycosis Fungoides Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Mycosis Fungoides Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Mycosis Fungoides Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Mycosis Fungoides Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Mycosis Fungoides Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Mycosis Fungoides Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Mycosis Fungoides Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Mycosis Fungoides Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Mycosis Fungoides Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Mycosis Fungoides Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Mycosis Fungoides Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Mycosis Fungoides Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Mycosis Fungoides Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst